The 778-subject PROGRESS trial tested Qulipta in migraine patients who had been experiencing headache on 15 or more days per month, for at least three months, with AbbVie's drug given as either 60 ...
AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy. Botox is prescribed for the prevention of headaches in adults diagnosed ...
Hosted on MSN10mon
What's Going On AbbVie Stock On Friday?In 2023, Qulipta generated sales of $408 million, with fourth-quarter 2023 sales of $114 million. AbbVie raised its long-term outlook for Ubrelvy and Qulipta revenues and expects peak combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback